Abstract
Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 214-219 |
| Number of pages | 6 |
| Journal | Gynecologic Oncology |
| Volume | 27 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1987 |
Fingerprint
ASJC Scopus subject areas
- Obstetrics and Gynecology
- Oncology
Cite this
Phase II trial of vinblastine in previously treated patients with ovarian cancer : A Southwest Oncology Group study. / Surwit, E. A.; Alberts, David S; O'Toole, R. V.; Graham, V.; Hannigan, E. V.; Stephens, R. L.; Boutselis, J. G.
In: Gynecologic Oncology, Vol. 27, No. 2, 1987, p. 214-219.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of vinblastine in previously treated patients with ovarian cancer
T2 - A Southwest Oncology Group study
AU - Surwit, E. A.
AU - Alberts, David S
AU - O'Toole, R. V.
AU - Graham, V.
AU - Hannigan, E. V.
AU - Stephens, R. L.
AU - Boutselis, J. G.
PY - 1987
Y1 - 1987
N2 - Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.
AB - Sixty-eight patients with relapsing, epithelial type ovarian carcinoma were entered into a Phase II study of vinblastine. Vinblastine was administered as a continuous intravenous infusion over five days at a starting dose of 1.7 mg/m2/day every 3 weeks. There were 44 fully evaluable and 6 partially evaluable patients. Forty-one of these patients had had only one prior treatment regimen. Grade 3 or 4 leukopenia occurred in 12 patients (24%), but Grade 3 or 4 thrombocytopenia occurred in only 2 patients. There were two clinical complete responses of 18 and 36 weeks duration and one partial response of 6 weeks for an overall response rate of 7%. We conclude that vinblastine, administered in optimal dose and schedule, has little clinical activity in previously treated patients with ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=0023258160&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023258160&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(87)90295-2
DO - 10.1016/0090-8258(87)90295-2
M3 - Article
C2 - 3570059
AN - SCOPUS:0023258160
VL - 27
SP - 214
EP - 219
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 2
ER -